Eric Cantor, who led House Republicans from 2011 to 2014, has been named president and chief executive officer of the Pharmaceutical Research and Manufacturers of America, the industry's most powerful lobbying group. He starts in November.
The move hands PhRMA—which represents more than 30 major drugmakers including Pfizer and Johnson & Johnson—a insider with direct experience in legislative strategy and congressional power dynamics. Cantor's 14 years in the House, including his rise to Majority Leader, gives the group a figure who understands both the mechanics of passing bills and the informal networks that drive Capitol Hill decisions.
PhRMA faces intensifying pressure from Congress on drug pricing, patent protections, and research funding. The group has already clashed with lawmakers over transparency and affordability. Cantor's appointment signals the industry's intent to press its case through someone who can facing those fights from the inside.
Cantor's move mirrors a long-running Washington pattern: prominent former members cash in by leading trade groups and lobbying shops that capitalize on their relationships and knowledge of legislative procedure. The practice has drawn recurring criticism from ethics watchdogs and government reform advocates, though it remains standard in the lobbying world.
As PhRMA chief, Cantor will shape the industry's response to healthcare reform proposals and direct its engagement with federal regulators and lawmakers. Drug pricing and intellectual property protection are expected to dominate his agenda.
